Rezolute (RZLT) to Release Quarterly Earnings on Tuesday

Key Points

• Rezolute will report Q3 2026 results after the market closes on Tuesday, May 12, with analysts expecting earnings of about ($0.1686) per share; an earnings call is scheduled for Wednesday, May 13 at 4:00 PM ET.
• The company missed last quarter (reported ($0.22) vs. consensus ($0.16)), and analysts now forecast roughly -$1 EPS for both the current and next fiscal year.
• RZLT trades around $3.29 with a market cap near $314M, has mixed analyst coverage (6 Buy / 4 Hold / 1 Sell) and an average price target of $8.00, while institutional investors own about 82.97% of the shares.

Rezolute (NASDAQ:RZLT - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.1686) per share for the quarter. Investors can check the company's upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Thursday, February 12th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.06). On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Stock Performance

NASDAQ:RZLT traded down $0.02 during mid-day trading on Tuesday, reaching $3.29. The stock had a trading volume of 532,754 shares, compared to its average volume of 2,879,322. The firm has a 50 day moving average price of $3.15 and a two-hundred day moving average price of $4.87. The stock has a market capitalization of $314.37 million, a P/E ratio of -3.53 and a beta of 0.66. Rezolute has a one year low of $1.07 and a one year high of $11.46.

Wall Street Analysts Forecast Growth

RZLT has been the subject of several recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Rezolute in a research report on Tuesday, April 21st. Wedbush upgraded Rezolute from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $2.00 to $5.00 in a research report on Wednesday, March 25th. Finally, BTIG Research reiterated a "buy" rating and issued a $5.00 price objective on shares of Rezolute in a research report on Thursday, January 8th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Rezolute has an average rating of "Hold" and an average price target of $8.00.

Institutional Trading of Rezolute

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in Rezolute by 5.0% in the third quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company's stock valued at $312,000 after purchasing an additional 1,567 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Rezolute by 5.5% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,659 shares of the company's stock valued at $363,000 after acquiring an additional 2,014 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Rezolute by 8.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 45,088 shares of the company's stock valued at $107,000 after acquiring an additional 3,630 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Rezolute during the second quarter valued at approximately $25,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Rezolute during the third quarter valued at approximately $61,000. Institutional investors own 82.97% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.